Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
ConditionPituitary Adenoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMayo Clinic
About this trial
The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.
Eligibility criteria
Qualifiers
Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.
Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.
Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.
Able to provide informed consent and be capable of completing the imaging protocols.
Disqualifiers
Patients with contraindications to MRI or PET scans.
Patients with known allergies to contrast agents or other imaging-related materials.
Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).
Patients with successful MRI localization of the adenoma.
Trial design
Treatments tested in this trial
- FET-PET/MRI
Treatment groups
5 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov